Titan Pharmaceuticals Stock

TTNP

US8883147055

Market Closed - Nasdaq 06:00:00 05/09/26 am AEST			5-day change	1st Jan Change
0.4203 ^USD	-2.28%		-4.24%	-90.88%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation : Titan Pharmaceuticals

Market Cap	6.13M 5.27M 4.96M 4.53M 8.47M 580M 8.5M 58.81M 22.73M 297M 23.03M 22.53M 946M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.84M 2.67M 2.44M 4.56M 312M 4.57M 31.66M 12.24M 160M 12.4M 12.13M 509M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news : Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
15/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
15/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
02/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
21/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations : Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
19/02/21	Titan Pharmaceuticals : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases : Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
28/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	USD 0.4203	-2.28%	66,714
03/09/26	USD 0.4301	+1.75%	118,572
02/09/26	USD 0.4227	+5.07%	182,266
01/09/26	USD 0.4023	-2.83%	114,040
31/08/26	USD 0.4140	-5.67%	155,047

Delayed Quote Nasdaq

More quotes

1 year	0.42	4.8
3 years	0	14.8
5 years	0	43
10 years	0	23,040.03

	2023	2024
Net sales	184K 158K 149K 136K 254K 17.4M 255K 1.76M 682K 8.91M 691K 676K 28.39M	-
Net income	-5.57M -4.79M -4.5M -4.11M -7.69M -527M -7.72M -53.41M -20.64M -270M -20.91M -20.46M -859M	-4.71M -4.05M -3.81M -3.47M -6.5M -445M -6.52M -45.13M -17.45M -228M -17.67M -17.29M -726M
Net Debt	-6.2M -5.33M -5.01M -4.57M -8.55M -586M -8.58M -59.41M -22.97M -300M -23.26M -22.76M -956M	-2.83M -2.43M -2.29M -2.09M -3.91M -268M -3.92M -27.15M -10.49M -137M -10.63M -10.4M -437M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation : Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news : Titan Pharmaceuticals

Analysts' recommendations : Titan Pharmaceuticals

Press Releases : Titan Pharmaceuticals

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	-2.28%
Current month	-90.88%
Current year	-90.88%